Icosavax Inc - ESG Rating & Company Profile powered by AI
If you are employed by Icosavax Inc and you would like to licence your ESG aseessment, please contact us. This assessment of Icosavax Inc leverages information from across the internet as well as from available disclosures by Icosavax Inc. This Sustainability score for Icosavax Inc represents its reporting of the UN Sustainable Development Goals.
Icosavax Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.9; made up of an environmental score of 3.2, social score of 6.4 and governance score of 8.0.
5.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 669 | Viridian Therapeutics Inc | 6.0 | High |
| 669 | Vistin Pharma ASA | 6.0 | High |
| 716 | Icosavax Inc | 5.9 | High |
| 716 | Akeso Inc | 5.9 | High |
| 716 | Alfresa Holdings Corp | 5.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Icosavax Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Icosavax Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Icosavax Inc report the average age of the workforce?
Sign up for free to unlockDoes Icosavax Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Icosavax Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Icosavax Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Icosavax Inc offer flexible work?
Sign up for free to unlockDoes Icosavax Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Icosavax Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Icosavax Inc conduct supply chain audits?
Sign up for free to unlockDoes Icosavax Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Icosavax Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Icosavax Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Icosavax Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Icosavax Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Icosavax Inc disclose water use targets?
Sign up for free to unlockDoes Icosavax Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Icosavax Inc have a product recall in the last two years?
Sign up for free to unlockDoes Icosavax Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Icosavax Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Icosavax Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Icosavax Inc disclose parental leave metrics?
Sign up for free to unlockDoes Icosavax Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Icosavax Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Icosavax Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Icosavax Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Icosavax Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Icosavax Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Icosavax Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Icosavax Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Icosavax Inc disclose its waste policy?
Sign up for free to unlockDoes Icosavax Inc report according to TCFD requirements?
Sign up for free to unlockDoes Icosavax Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Icosavax Inc disclose energy use targets?
Sign up for free to unlockDoes Icosavax Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Icosavax Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Icosavax Inc
These potential risks are based on the size, segment and geographies of the company.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.